We have taken great steps towards changing Teva profoundly, in a way that further highlights what makes us unique in this industry
“We are creating breakthroughs in neurodegeneration. Teva’s National Network of Excellence will contribute to the quality of life of us all.”
“Copaxone and Azilect came from Israeli universities. Why wouldn’t we tap into this incredible expertise and innovation of Israeli Universities to find the next jewels.”
"Our single-minded focus, through the skills of our scientists, is to ensure that we bring essential generic medicines of high quality to the greatest number of in the fastest time possible."
“Today we can understand the processes resultingin disease and response to drugs in individual patients with greater precision than ever before.”
“Our NTE process reflects our expertise ingenerics and specialty drugs, and the synergiescreated when these capabilities are integrated.”
"Our collaboration with Teva will contribute greatly to the Korean pharmaceutical industry by supplying innovative medicines at affordable prices."
“In China there is an increasing demand forquality generic medication. We were very impressedby Teva's oncology, CNS and respiratory portfolio."
“Our DNA is the combination of P&G and Teva. Our mission is to understand what people wantand need, and then find innovative ways to deliver that.”
“We are excited to develop environmentally friendly technologies to create a healthier world for our customers worldwide.“
All News › Top News Sep 22, 2016 Teva Announces Positive Top-Line Data from Second Phase III Study of SD-809 in Tardive Dyskinesia (TD) Learn More Share Top News Sep 20, 2016 Teva and Regeneron Announce Global Collaboration to Develop and Commercialize Fasinumab, an Investigational NGF Antibody for Chronic Pain Learn More Share Top News Sep 19, 2016 Teva Announces Results from Exploratory 52-Week Phase 2 PRIDE-HD Study of Pridopidine in Huntington Disease Learn More Share Top News Sep 15, 2016 Teva Strengthens Injectables Portfolio with the Launch of an Authorized Generic of Cubicin® (Daptomycin for Injection) in the United States Learn More Share
Top News Sep 22, 2016 Teva Announces Positive Top-Line Data from Second Phase III Study of SD-809 in Tardive Dyskinesia (TD) Learn More
Top News Sep 20, 2016 Teva and Regeneron Announce Global Collaboration to Develop and Commercialize Fasinumab, an Investigational NGF Antibody for Chronic Pain Learn More
Top News Sep 19, 2016 Teva Announces Results from Exploratory 52-Week Phase 2 PRIDE-HD Study of Pridopidine in Huntington Disease Learn More
Top News Sep 15, 2016 Teva Strengthens Injectables Portfolio with the Launch of an Authorized Generic of Cubicin® (Daptomycin for Injection) in the United States Learn More
TAPI Launches New Website! TAPI has launched a new website with an enhanced product catalogue. TAPI continues to deliver high-quality APIs and committed customer service. Discover more
TAPI has launched a new website with an enhanced product catalogue. TAPI continues to deliver high-quality APIs and committed customer service.
New Plant in Croatia Croatian Prime Minister Tihomir Orešković opens Teva's new multi-purpose synthesis plant in Savski Marof. Discover more
Croatian Prime Minister Tihomir Orešković opens Teva's new multi-purpose synthesis plant in Savski Marof.
How Our Uniqueness Creates Healthcare Confidence Around the world, people know that our ultimate goal is their health and well-being. Find out how we do it:
Around the world, people know that our ultimate goal is their health and well-being. Find out how we do it: